Regulatory approval to commence Striate sales in Singapore
Filed with ASX · · 3 pages · English
Story so far
Earlier from Orthocell
- S&P DJI Announces March 2025 Quarterly Rebalance
- Orthocell Receives $3.18 million R&D Tax Refund
- Third Consecutive Quarter of Record Revenue for Orthocell
- US FDA Application Submitted for Remplir as US Launch Nears
- Major Milestone with First Sales of Remplir in Singapore
Later from Orthocell
- First Sales of Striate in Germany, Austria & Swiss Region
- Investor Presentation - US FDA 510(k) Clearance for Remplir
- Remplir Cleared to Commence Sales in US$1.6B US Market
- Regulatory Approval for Striate in US$65M Brazilian Market
- First US Distributors Signed for Remplirs US$1.6B market
Follow Orthocell into a list and get an email when it puts out news.
Follow Orthocell